论文部分内容阅读
目的探讨坎地沙坦和美托洛尔对扩张型心肌病患者血浆B型脑钠肽(BNP)水平及心功能的影响。方法 78例扩张型心肌病患者随机分为坎地沙坦和美托洛尔组(坎美组)和常规治疗组,50例健康受试者为正常对照组,检测坎美组和常规治疗组治疗前和治疗8周后脑钠肽水平,并通过超声心动图检测左室射血分数(LVEF)、左室短轴缩短率(FS)、二尖瓣血流最大流速E峰和A峰比值(E/A)、EF斜率的变化。结果扩张型心肌病患者BNP水平显著高于正常对照组。坎美组治疗8周后,BNP水平显著降低,LVEF、FS、E/A、EF斜率显著升高。结论坎地沙坦和美托洛尔性价比高,不良反应少,能显著降低扩张型心肌病患者BNP水平,改善心脏收缩和舒张功能,改善患者的长期预后。
Objective To investigate the effects of candesartan and metoprolol on plasma BNP level and cardiac function in patients with dilated cardiomyopathy. Methods 78 patients with dilated cardiomyopathy were randomly divided into candesartan and metoprolol group (Camille group) and conventional treatment group, 50 healthy subjects were normal control group, detection of Camry group and conventional treatment group Brain natriuretic peptide levels before and 8 weeks after treatment, and the left ventricular ejection fraction (LVEF), shortening rate of left ventricular fraction (Fs), maximum peak velocity of mitral flow E and peak A (E / A), EF slope change. Results BNP levels in patients with dilated cardiomyopathy were significantly higher than those in normal controls. After 8 weeks of treatment with Camry, BNP level decreased significantly, and the slope of LVEF, FS, E / A and EF increased significantly. Conclusions Candesartan and metoprolol are cost-effective and have few adverse reactions. They can significantly reduce BNP levels, improve systolic and diastolic function, and improve long-term prognosis in patients with dilated cardiomyopathy.